TABLE 3.
C1P stimulates hBD2 and hBD3 mRNA expression through STAT1 and STAT3 activation in extracutaneous epithelial cells
| Treatmenta | Relative mRNA expression versus vehicle controlb |
|||
|---|---|---|---|---|
| HeLa cells |
A549 cells |
|||
| hBD2 | hBD3 | hBD2 | hBD3 | |
| Vehicle | 1.0 ± 0.1 | 1.0 ± 0.4 | 1.0 ± 0.2 | 1.0 ± 0.1 |
| Fludarabine | 1.1 ± 0.1 | 0.8 ± 0.2 | 0.8 ± 0.2 | 0.9 ± 0.8 |
| STA-21 | 1.3 ± 0.1 | 0.7 ± 0.5 | 1.0 ± 0.2 | 1.6 ± 0.4 |
| C16C1P | 2.1 ± 0.2* | 4.0 ± 0.7* | 2.5 ± 0.3* | 8.9 ± 1.2* |
| C16C1P + fludarabine | 0.9 ± 0.3# | 1.0 ± 0.3# | 0.7 ± 0.1# | 3.3 ± 0.7# |
| C16C1P + STA-21 | 1.2 ± 0.2# | 1.2 ± 0.2# | 1.3 ± 0.3# | 4.3 ± 1.1# |
a
HeLa cells or A549 cells were pretreated with or without STAT1 inhibitor (fludarabine [10 μM]) or STAT3 inhibitor (STA-21 [2 μM]) for 30 min and then were incubated with C16C1P (1 μM) for 24 h.
b
Values are means ± SD (n = 3). *, P < 0.01 versus vehicle control; #, P < 0.01 versus C1P alone.